Dietary Insights and Nutritional Education in Adults on GLP-1 Therapy

Recruiting now · Not applicable

Conditions studied: Obesity Type 2 Diabetes Mellitus, Obesity

In brief

This pilot study will evaluate the feasibility, acceptability, and perceived usefulness of the SWITCH mobile nutrition behavioral intervention among adults receiving GLP-1 receptor agonist therapy for obesity and/or type 2 diabetes. Participants will complete baseline assessments, receive a 6-week app-based nutrition intervention consisting of daily dietary self-monitoring and weekly learning modules, and complete follow-up assessments and a structured interview.

Key facts

Study ID

NCT07518407

Run by

University of South Carolina

People needed

50

Starts

2026-04-06

Expected to finish

2027-04-01

Last updated by the study team

2026-06-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Age between 18 and 65 years.
• BMI between 30 - 49.9 kg/m2 and/or diagnosed with type 2 diabetes.
• Currently prescribed and using GLP-1 receptor therapy for at least 4 weeks.
• Own a smartphone (Android or iOS) with an active data plan to support app-based intervention delivery.
• Residing anywhere in the United States.
• Must be willing and able to reduce caloric intake.
• Be free of major health or psychiatric diseases, drug, or alcohol dependency.
• Willing to sign informed consent.

You may not qualify if…

• • Presence of type 1 diabetes mellitus
• Severe complications, including but not limited to proliferative retinopathy, severe peripheral neuropathy, nephropathy requiring dialysis, active foot ulcers, or recent hospitalization for diabetic ketoacidosis or hyperosmolar hyperglycemic state within the past 6 months.
• Current or recent (within 6 months) participation in another structured weight loss program or clinical trial that may interfere with study outcomes.
• Pregnancy, breastfeeding, or plans to become pregnant during the study period.
• Current use of another investigational weight loss device or medication.
• Diagnosed eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder) or other psychiatric conditions that may affect adherence to behavioral interventions, as determined by study staff.
• Severe cardiovascular, hepatic, renal, or pulmonary disease that would limit participation in moderate physical activity or dietary modification.
• Active cancer treatment (chemotherapy, radiation, or surgery) within the past 12 months.
• Substance use disorder or alcohol dependency within the past 12 months.
• Cognitive impairment or any medical or mental condition that would interfere with the ability to understand or comply with study procedures.
• Lack of reliable internet or smartphone access, or unwillingness to use a mobile app for tracking and communication.

Where it is running

• University South Carolina — Columbia, South Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.